Ram Govindan

Ram Govindan, a clinical investigator from Washington University specializing in non-small cell lung cancer, joins Stephen Liu from Georgetown University, who focuses on innovative immunotherapy treatments. They discuss groundbreaking advancements in combining chemotherapy with immunotherapy, showing improved survival rates. The conversation highlights the potential of bispecific therapies and antibody-drug conjugates, as well as the role of biomarkers in personalizing treatment. They also touch on emerging strategies like TDXD for HER2 mutations, shaping the future of lung cancer therapy.